🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the fight against drug-resistant strains of the infection, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with figures suggesting over 82 million infections annually. Especially elevated rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the face of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Health officials are increasingly worried about the surge in drug-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

One new antibiotic, also known as a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists believe that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in concurrent days. This medication, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The charitable organization GARDP worked alongside the drug firm Innoviva to see it through.

“This authorization marks a major breakthrough in the management of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

Based on data published in a prominent scientific publication, zoliflodacin eradicated over nine in ten of uncomplicated infections. This places it at an comparable level with the current standard treatment, which combines two antibiotics. The trial involved nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to make available and distribute the drug in many developing nations.

Clinicians on the front lines have voiced positive views. Having a single-dose, oral treatment such as this is seen as a "game-changer" for gonorrhoea control. This is deemed essential to alleviate the strain of the illness for patients and to halt the transmission of extremely resistant gonorrhoea globally.